These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Wendt T; Bucciarelli L; Qu W; Lu Y; Yan SF; Stern DM; Schmidt AM Curr Atheroscler Rep; 2002 May; 4(3):228-37. PubMed ID: 11931721 [TBL] [Abstract][Full Text] [Related]
8. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075 [TBL] [Abstract][Full Text] [Related]
9. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Yamagishi S; Nakamura K; Matsui T; Ueda S; Fukami K; Okuda S Expert Opin Investig Drugs; 2008 Jul; 17(7):983-96. PubMed ID: 18549336 [TBL] [Abstract][Full Text] [Related]
10. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy. Takeuchi M; Takino J; Yamagishi S Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971 [TBL] [Abstract][Full Text] [Related]
11. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes. Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646 [TBL] [Abstract][Full Text] [Related]
12. Recent progress in advanced glycation and diabetic vascular disease: role of advanced glycation end product receptors. Vlassara H; Bucala R Diabetes; 1996 Jul; 45 Suppl 3():S65-6. PubMed ID: 8674896 [TBL] [Abstract][Full Text] [Related]
13. The role of advanced glycation in the pathogenesis of diabetic retinopathy. Stitt AW Exp Mol Pathol; 2003 Aug; 75(1):95-108. PubMed ID: 12834631 [TBL] [Abstract][Full Text] [Related]
14. Recent progress in advanced glycation end products and diabetic complications. Vlassara H Diabetes; 1997 Sep; 46 Suppl 2():S19-25. PubMed ID: 9285494 [No Abstract] [Full Text] [Related]
15. RAGE: a new target for the prevention and treatment of the vascular and inflammatory complications of diabetes. Schmidt AM; Stern DM Trends Endocrinol Metab; 2000 Nov; 11(9):368-75. PubMed ID: 11042467 [TBL] [Abstract][Full Text] [Related]
17. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus. Lee J; Yun JS; Ko SH Nutrients; 2022 Jul; 14(15):. PubMed ID: 35956261 [TBL] [Abstract][Full Text] [Related]
18. [Possible participation of advanced glycation endproducts and their receptor system in the development of diabetic vascular complications]. Yamamoto Y; Sakurai S; Watanabe T; Yonekura H; Yamamoto H Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):49-55. PubMed ID: 12617038 [TBL] [Abstract][Full Text] [Related]
19. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy. Yoon SJ; Yoon YW; Lee BK; Kwon HM; Hwang KC; Kim M; Chang W; Hong BK; Lee YH; Park SJ; Min PK; Rim SJ Exp Mol Med; 2009 Nov; 41(11):802-11. PubMed ID: 19641377 [TBL] [Abstract][Full Text] [Related]
20. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]